论文部分内容阅读
目的通过对结核分枝杆菌MIC的测定,初步探讨利福平和利福布汀两药间的交叉耐药率。方法利用Alarmar Blue法(Alamar blue susceptibility test,MABA)检测116株结核分枝杆菌临床分离株对利福平和利福布汀的体外MIC。结果 36株利福平敏感株均对利福布汀敏感;80株利福平耐药株中有58株对利福布汀也同时耐药(对利福布汀的MIC>0.5 ug/ml),利福平与利福布汀间的交叉耐药率为72.5%(58/80);同时对利福平和利福布汀耐药的菌株对两种药物的耐药程度呈现正相关。结论利福布汀较利福平有更好的体外抗菌活性。对于利福平耐药而利福布汀敏感的患者仍可选择利福布汀作为联合化疗的有效药物之一。
Objective To determine the MIC of rifampicin and rifabutin by measuring the MIC of Mycobacterium tuberculosis. Methods The in vitro MIC of 116 Mycobacterium tuberculosis clinical isolates against rifampicin and rifabutin was detected by Alarmar blue susceptibility test (MABA). Results 36 susceptible strains of rifampicin were sensitive to rifabutin; 58 of rifampin-resistant strains were resistant to rifabutin (MIC> 0.5 μg / ml for rifabutin) ). The rate of cross-resistance between rifampicin and rifabutin was 72.5% (58/80). Meanwhile, the rifampin-resistant and rifabutin-resistant strains showed a positive correlation with the drug resistance of the two drugs. Conclusion Rifabutin has better antibacterial activity than rifampicin in vitro. For rifampin-resistant patients, rifabutin may still be selected as one of the effective agents for combination chemotherapy.